Eval. of Subconjunctival Sirolimus in Treatment of Bilateral Geographic Atrophy

评估。

• 批准号: 8339803
• 负责人: Frederick Ferris
• 金额: $ 11.47万
• 依托单位: NATIONAL EYE INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8339803
• 关键词: Affect; Age related macular degeneration; Area; Bilateral; Cells; Drusen; Eye; Fundus photography; Image; Inflammation; Injection of therapeutic agent; Masks; Measures; Outcome; Participant; Patients; Pharmaceutical Preparations; Reading; Relative (related person); Retina; Safety; Sirolimus; Vision; base; digital; geographic atrophy; macula; prevent; primary outcome; secondary outcome

This study will determine if a drug called sirolimus is safe to give to people with geographic atrophy GA and if it can help preserve vision in patients. GA is an advanced form of dry age-related macular degeneration (AMD). AMD affects the macula, the central part of the retina needed for sharp, clear vision. There are two types of AMD, wet and dry. In dry AMD, cells in the macula die.GA may at least partly be caused by inflammation. Sirolimus helps prevent inflammation and therefore may help treat GA.

这项研究将确定一种名为西罗莫司的药物是否可以安全地用于地图状萎缩症患者，以及它是否可以帮助保护患者的视力。GA是干性年龄相关性黄斑变性（AMD）的晚期形式。AMD影响黄斑，视网膜的中心部分需要敏锐，清晰的视觉。有两种类型的AMD，湿型和干型。在干性AMD中，黄斑中的细胞死亡。GA可能至少部分由炎症引起。西罗莫司有助于预防炎症，因此可能有助于治疗GA。